Use of acyl-homoserine lactone derivatives as anti-thrombotic agents

1. A method of inhibiting platelets from becoming hypersensitive, the method comprising administering an effective amount of an acyl-homoserine lactone to a patient in need thereof; and inhibiting platelets in the patient from becoming hypersensitive; the acyl-homoserine lactone compound having Formula (I):

wherein R1 is a carbonyl, and R2 is (CH 2 ) n CH 3 where n ranges from 4 to 8; and wherein the patient in need has lupus.

2. The method of claim 1 , wherein the acyl-homoserine lactone compound consists essentially of 12C-AHL, having Formula II:

3. The method of claim 1 , wherein the acyl-homoserine lactone compound consists essentially of 10C-AHL, having Formula III:

4. The method of claim 1 , wherein the acyl-homoserine lactone compound consists essentially of 8C-AHL, having Formula IV:

5. The method of claim 1 , wherein the acyl-homoserine lactone compound is administered at an effective concentration, and the acyl-homoserine lactone compound inhibits aggIgG-mediated platelet activation.

6. The method of claim 1 , wherein the acyl-homoserine lactone compound is administered at a concentration of about 200 μM or less, and the acyl-homoserine lactone compound inhibits thrombin-induced platelet activation.

7. The method of claim 1 , wherein the acyl-homoserine lactone compound inhibits signaling activities in the platelets.

8. The method of claim 1 , wherein the patient has a pro-thrombotic condition.

9. The method of claim 1 , wherein the acyl-homoserine lactone compound is co-administered with at least one lupus treatment.

10. The method of claim 9 , wherein the lupus treatment is selected from the group consisting of: PI3 kinase inhibitors; corticosteroids; anti-inflammatory agents; immunosuppressants; anti-malarial drugs.